The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CBLL | -56.64% | N/A | N/A | -54% |
| S&P | +19.89% | +109.18% | +15.89% | +18% |
Ceribell focuses on making electroencephalography (EEG) widely accessible, more efficient, and more cost-effective. The company creates and validates an FDA cleared instant EEG system that does not require an EEG technologist or specialist interpreter, which allows for faster results and clinical decision-making. The Ceribell EEG System can be set up by any healthcare provider in 6 minutes and offers a proprietary Brain Stethoscope function that dramatically simplifies interpretation of EEG results by converting brainwaves to sound so seizures can be detected by listening. Earlier diagnosis and focused treatment for patients with seizures, including non-convulsive seizures that can only be diagnosed with EEG, can significantly lower mortality, secondary brain injury, length of stay, and risk of complications.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $21.20M | 0.0% |
| Gross Profit | $18.68M | 0.0% |
| Gross Margin | 88.13% | 0.0% |
| Market Cap | $676.96M | 0.0% |
| Market Cap / Employee | $2.41M | 0.0% |
| Employees | 281 | 0.0% |
| Net Income | -$13.64M | 0.0% |
| EBITDA | -$14.63M | 0.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $40.14M | 0.0% |
| Accounts Receivable | $12.31M | 0.0% |
| Inventory | 6 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $20.41M | 0.0% |
| Short Term Debt | $1.15M | 0.0% |
| Current | YOY Change | |
|---|---|---|
| Return On Invested Capital | -49.30% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.60M | 0.0% |
| Operating Free Cash Flow | -$7.53M | 0.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | -6.82 | 3.60 | 3.72 | - | |
| Price to Sales | 8.78 | - | |||
| Price to Tangible Book Value | -6.79 | 3.61 | 3.73 | - | |
| Enterprise Value to EBITDA | -60.34 | -38.09 | -35.82 | - | |
| Total Debt | $22.13M | $21.96M | $21.76M | $21.55M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
